The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor
暂无分享,去创建一个
Deric M. Park | Karlyne M. Reilly | P. Gardner | C. Snyderman | J. Levy | K. Reilly | J. Butman | B. Widemann | E. Dombi | E. Bouffet | M. Miettinen | J. Gulley | S. MacDonald | R. Malyapa | N. Rowan | C. Heery | Maran Ilanchezhian | J. Glod | M. Raygada | G. Cote | M. F. Wedekind | Sadhana Jackson | J. Sommer | D. Dix | R. Lockridge | S. Lozinsky | Debraj Mukherjee | Abby B Sandler | Sarah Fuller | Liny John | Hannah Smith | B. J. Thomas | Taryn Allen | Abby B. Sandler
[1] Steven J. M. Jones,et al. Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury , 2021, npj Precision Oncology.
[2] J. Schlom,et al. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer , 2021, Journal for ImmunoTherapy of Cancer.
[3] H. K. Haugland,et al. Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of 9 cases, including uncommon features of a relatively under-recognized entity. , 2021, Annals of diagnostic pathology.
[4] Deric M. Park,et al. Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma , 2021, The oncologist.
[5] Zongyang Yu,et al. Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report , 2020, Frontiers in Oncology.
[6] O. Jaber,et al. Metastatic poorly differentiated chordoma: the eyes do not see what the mind does not know , 2019, Autopsy & case reports.
[7] J. Schlom,et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors , 2019, Journal of Immunotherapy for Cancer.
[8] F. Soylemezoğlu,et al. Poorly differentiated chordoma: review of 53 cases , 2019, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[9] Y. Yamada,et al. Treatment of dedifferentiated chordoma: a retrospective study from a large volume cancer center , 2019, Journal of Neuro-Oncology.
[10] Liming Cheng,et al. Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review , 2019, Front. Oncol..
[11] F. Valvo,et al. MRI evaluation of sacral chordoma treated with carbon ion radiotherapy alone. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] S. Rane,et al. Poorly Differentiated Chordomas Showing Loss of INI1/SMARCB1: A Report of 2 Rare Cases With Diagnostic Implications , 2018, International journal of surgical pathology.
[13] G. Nielsen,et al. Clinicopathologic characteristics of poorly differentiated chordoma , 2018, Modern Pathology.
[14] C. Antonescu,et al. High sensitivity of FISH analysis in detecting homozygous SMARCB1 deletions in poorly differentiated chordoma: a clinicopathologic and molecular study of nine cases , 2018, Genes, chromosomes & cancer.
[15] C. Hong,et al. Poorly differentiated chordoma with loss of SMARCB1/INI1 expression in pediatric patients: A report of two cases and review of the literature , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.
[16] Matthew D. Young,et al. The driver landscape of sporadic chordoma , 2017, Nature Communications.
[17] S. Stacchiotti,et al. Medical treatment of advanced chordomas. , 2017, European journal of cancer.
[18] A. Bennett,et al. Symptom burden and life challenges reported by adult chordoma patients and their caregivers , 2017, Quality of Life Research.
[19] F. Sim,et al. How Does the Level of Nerve Root Resection in En Bloc Sacrectomy Influence Patient-Reported Outcomes? , 2017, Clinical orthopaedics and related research.
[20] J. Drake,et al. Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature , 2016, Journal of Clinical Neuroscience.
[21] Kathleen E. Fenerty,et al. Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST , 2016, BMC Cancer.
[22] C. Kearns,et al. Fifty-four-month survival in a 3-year-old child presenting with an aggressive metastatic dedifferentiated clival chordoma , 2016, BMJ Case Reports.
[23] Kevin M. Curtis,et al. Characteristics and Patterns of Metastatic Disease from Chordoma , 2015, Sarcoma.
[24] F. Bourdeaut,et al. Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors? , 2014, Cancer genetics.
[25] C. Sarkar,et al. Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas. , 2014, Neuro-oncology.
[26] B. Korf,et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials , 2013, Neurology.
[27] M. Al-Rahawan,et al. Durable complete response to chemotherapy in an infant with a clival chordoma , 2012, Pediatric blood & cancer.
[28] J. Finlay,et al. The role of chemotherapy in pediatric clival chordomas , 2011, Journal of Neuro-Oncology.
[29] Julie M. Batten,et al. Recurrent Chromosomal Copy Number Alterations in Sporadic Chordomas , 2011, PloS one.
[30] C. Antonescu,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.
[31] J. McKenney,et al. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas , 2010, Acta Neuropathologica.
[32] F. Marandino,et al. Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients , 2010, BMC Cancer.
[33] A. Folpe,et al. Clinical and Histopathologic Features of Chordomas in Children and Young Adults , 2010, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[34] Jaewon Min,et al. Identification of Rad51 regulation by BRCA2 using Caenorhabditis elegans BRCA2 and bimolecular fluorescence complementation analysis. , 2007, Biochemical and biophysical research communications.
[35] G. Nielsen,et al. Base of Skull Chordomas in Children and Adolescents: A Clinicopathologic Study of 73 Cases , 2006, The American journal of surgical pathology.
[36] M H Deverell,et al. Three‐dimensional reconstruction of human embryonic notochords: Clue to the pathogenesis of chordoma , 1993, The Journal of pathology.
[37] C. Congdon. Benign and malignant chordomas; a clinico-anatomical study of twenty-two cases. , 1952, The American journal of pathology.
[38] H. Sharma,et al. An Atypical Presentation of Chordoma: Case Report and Review , 2017 .